Barclays PLC Has $1.05 Million Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

Barclays PLC lifted its holdings in Arbutus Biopharma Co. (NASDAQ:ABUSFree Report) by 466.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 272,029 shares of the biopharmaceutical company’s stock after purchasing an additional 223,995 shares during the quarter. Barclays PLC’s holdings in Arbutus Biopharma were worth $1,047,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ABUS. Helen Stephens Group LLC bought a new position in shares of Arbutus Biopharma during the third quarter worth about $50,000. XTX Topco Ltd bought a new position in shares of Arbutus Biopharma during the 2nd quarter worth approximately $53,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Arbutus Biopharma by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 36,309 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 14,138 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Arbutus Biopharma in the third quarter worth $142,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Arbutus Biopharma by 453.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 30,723 shares during the last quarter. 43.79% of the stock is owned by institutional investors.

Arbutus Biopharma Stock Performance

Shares of NASDAQ:ABUS opened at $3.18 on Wednesday. The company has a 50-day simple moving average of $3.45 and a 200 day simple moving average of $3.72. The company has a market capitalization of $602.58 million, a P/E ratio of -7.40 and a beta of 1.78. Arbutus Biopharma Co. has a 52-week low of $2.21 and a 52-week high of $4.72.

Analysts Set New Price Targets

Several brokerages have commented on ABUS. Chardan Capital reissued a “buy” rating and set a $5.00 price target (up from $4.50) on shares of Arbutus Biopharma in a research report on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Monday, November 18th. Finally, JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Arbutus Biopharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

View Our Latest Stock Analysis on Arbutus Biopharma

Arbutus Biopharma Profile

(Free Report)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.

Recommended Stories

Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Co. (NASDAQ:ABUSFree Report).

Institutional Ownership by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.